Antibody targeting osteoclast-related protein siglec-15

Patent metadata

Field	Value
Publication number	US-9815899-B2
Application number	US-201514826515-A
Country	US
Kind code	B2
Filing date	Aug 14, 2015
Priority date	Oct 11, 2007
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

First claim

The invention claimed is:

1. An antibody or an antigen binding fragment thereof, which specifically binds to any one of the following polypeptides (a)-(d), or any combination thereof, and inhibits osteoclast formation and/or osteoclastic bone resorption:
(a) amino acid residues 21 to 328 of the amino acid sequence of SEQ ID NO: 2;
(b) amino acid residues 21 to 260 of the amino acid sequence of SEQ ID NO: 2;
(c) amino acid residues 21 to 341 of the amino acid sequence of SEQ ID NO: 4; or
(d) amino acid residues 21 to 258 of the amino acid sequence of SEQ ID NO: 4.

2. The antibody or antigen binding fragment of claim 1 , wherein the antibody is a monoclonal antibody.

3. The antibody or antigen binding fragment of claim 1 , wherein the antibody is an IgG antibody.

4. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable diluent or carrier.

5. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition further comprises at least one agent selected from the group consisting of bisphosphonate, active vitamin D 3 , calcitonin, hormones, ipriflavone, vitamin K 2 (menatetrenone), calcium, PTH (parathyroid hormone), nonsteroidal anti-inflammatory agent, soluble TNF receptor, anti-TNF-αantibody or an antigen binding fragment thereof, anti-PTHrP (parathyroid hormone-related protein) antibody or an antigen binding fragment thereof, anti-IL-6 receptor antibody or an antigen binding fragment thereof, anti-RANKL antibody or an antigen binding fragment thereof, and OCIF (osteoclastogenesis inhibitory factor).

Assignees

• Daiichi Sankyo Co Ltd

Inventors

• Hiruma Yoshiharu
• Tsuda Eisuke

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title